Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares of Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $63.01, for a total transaction of $1,260,200.00. Following the completion of the transaction, the chief executive officer directly owned 1,272,987 shares of the company’s stock, valued at $80,210,910.87. This represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Apogee Therapeutics Trading Down 0.2%

Shares of NASDAQ APGE opened at $62.97 on Friday. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $64.87. The business has a 50-day moving average price of $47.56 and a two-hundred day moving average price of $42.07. The firm has a market capitalization of $2.90 billion, a PE ratio of -14.38 and a beta of 1.50.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.03. Research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Apogee Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its stake in Apogee Therapeutics by 99.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after buying an additional 383 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after acquiring an additional 246 shares during the period. Brooklyn Investment Group bought a new position in shares of Apogee Therapeutics during the first quarter valued at $42,000. AlphaQuest LLC acquired a new stake in shares of Apogee Therapeutics in the 1st quarter valued at $43,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after purchasing an additional 272 shares during the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on APGE. Mizuho initiated coverage on Apogee Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 price objective on the stock. Zacks Research cut shares of Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Citigroup restated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. Finally, Royal Bank Of Canada raised their price objective on Apogee Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Apogee Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $96.50.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.